To the Editor In their randomized clinical trial, Falandry et al1 reported that in a population of vulnerable patients 70 years and older, single-agent carboplatin was associated with significantly worse outcomes than either conventional every-3-weeks or weekly carboplatin–paclitaxel. These results suggest that even vulnerable older women with newly diagnosed ovarian cancer should be offered a conventional carboplatin–paclitaxel combination regimen. Although all patients in the monotherapy group received carboplatin at an area under the curve of 5 mg/mL·min, similar to the every-3-weeks carboplatin–paclitaxel group, it is difficult to understand why the group receiving less-intense treatment had the worst feasibility. While this is an important clinical study that addresses an important clinical question, there are some concerns regarding the interpretation of this study.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ito K, Shimomura A. What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer? JAMA Oncol. 2021;7(11):1726–1727. doi:10.1001/jamaoncol.2021.4128
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.